Although experimental evidence suggests calcium-sensing receptor (CASR) as a tumor-suppressor, the prognostic role of tumor CASR expression in colorectal carcinoma remains unclear. We hypothesized that higher tumor CASR expression might be associated with improved survival among colorectal cancer patients. We evaluated tumor expression levels of CASR by immunohistochemistry in 809 incident colorectal cancer patients within the Nurses' Health Study and the Health Professionals Follow-up Study. We used Cox proportional hazards regression models to estimate multivariable hazard ratio (HR) for the association of tumor CASR expression with colorectal cancer-specific and all-cause mortality. We adjusted for potential confounders including tumor biomarkers such as microsatellite instability, CpG island methylator phenotype, LINE-1 methylation level, expressions of PTGS2, VDR and CTNNB1 and mutations of KRAS, BRAF and PIK3CA. There were 240 colorectal cancerspecific deaths and 427 all-cause deaths. The median follow-up of censored patients was 10.8 years (interquartile range: 7.2, 15.1). Compared with patients with no or weak expression of CASR, the multivariable HRs for colorectal cancer-specific mortality were 0.80 [95% confidence interval (CI): 0.55-1.16] in patients with moderate CASR expression and 0.50 (95% CI: 0.32-0.79) in patients with intense CASR expression (p-trend 5 0.003). The corresponding HRs for overall mortality were 0.85 (0.64-1.13) and 0.81 (0.58-1.12), respectively. Higher tumor CASR expression was associated with a lower risk of colorectal cancer-specific mortality. This finding needs further confirmation and if confirmed, may lead to better understanding of the role of CASR in colorectal cancer progression.
The calcium sensing receptor (CASR) is a ubiquitously expressed G-protein coupled receptor and acts as the master regulator of the calcium homeostasis.
1 CASR serves as the molecular sensor of ionized calcium (Ca 21 ). Binding of Ca 21 to the CASR propagates intracellular signaling cascades which are critical in both physiologic and pathologic states. 2 Also, CASR has pleiotropic effects and can regulate gene expression, inflammation, cell proliferation, cell differentiation and apoptosis. [3] [4] [5] Deregulation of CASR has been implicated in different types of benign or malignant tumors of prostate, breast, parathyroid and colon. 3, [6] [7] [8] [9] [10] [11] Although the underlying mechanisms are not completely understood, higher calcium intake was associated with a lower risk of colorectal cancer in most epidemiological studies. 12, 13 Experimental studies reported a possible role of CASR in inhibiting proliferation of colonic epithelia.
14 CASR knockout mice showed increased incidence of formation of preneoplastic lesion of crypt foci in the colon, 15 and elevated inflammatory markers in colon epithelium, as well as more susceptibility to chemically induced colitis compared with the colons of wild type mice. 15, 16 In addition, treatment with a calcimimetic sensitized colon cancer cells to the chemoprotective function of calcium and inhibited cell growth. 3 Moreover, expression of CASR was decreased in advanced colorectal adenomas and undifferentiated tumors. 17 Furthermore, recent evidence indicates the role of epigenetic changes such as promoter hypermethylation, histone deacetylation and noncoding RNA involvement in the regulation of CASR expression. 18, 19 Collectively, these lines of evidence indicate that CASR expression and function regulate a fine balance between proliferation, differentiation and apoptosis. 3 Despite these biological data, the association between tumor CASR expression with survival among colorectal cancer patients has not specifically been examined. We hypothesized that tumor CASR expression is associated with colorectal cancer specific survival independent of other molecular and clinical characteristics.
To test this hypothesis, we utilized two prospective cohorts of women (the Nurses' Health Study, NHS) and men (the Health Professionals Follow-up Study, HPFS). Because both cohorts provide detailed data on major tumor molecular features, including tumor status of microsatellite instability (MSI), CpG island methylator phenotype (CIMP), long interspersed nucleotide element-1 (LINE-1) methylation level and KRAS, BRAF and PIK3CA mutations, we were able to evaluate the independent association of tumor CASR expression with patient-related outcomes.
Patients and Methods

Study population
The study population consisted of the participants of two large prospective cohort studies, the NHS (N 5 121,700 women observed since 1976) and HPFS (N 5 51,529 men observed since 1986, HPFS). Since the baseline, participants have completed questionnaires regarding information on What's new? New data reveal that higher expression of calcium-sensing receptor (CASR) may herald a better chance of surviving colorectal cancer. These authors set out to expand on prior findings, which showed that CASR expression in cultured cells correlated with increased apoptosis markers and fewer proliferation markers. In this study, they tested 809 cancer cases from the Nurses' Health Study and Health Professionals Follow-up Study, looking for CASR. Patients whose tumors carried lots of the receptor proved much less likely to die of colorectal cancer-and slightly less likely to die of any cause-than those whose tumors had only scant CASR, or none.
demographics, medical history and lifestyle factors every two years. The study was approved by the institutional review board at Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health.
Ascertainment of cases of colorectal cancer, tumor tissue collection and mortality measurements Participants were asked on biennial questionnaires to report a diagnosis of colorectal cancer and other diseases. Study physicians received permission from study participants or next-of-kin (for deceased) to obtain their medical records and pathological reports on colorectal cancer.
Study physicians who were unaware of tumor CASR levels and other molecular data, confirmed the incidence of colorectal cancer and recorded the information on disease stage, tumor location and histological type of the cancer. For deceased participants with known or suspected cancer for which we have not been able to obtain medical records, we contacted the state tumor registry to confirm and classify the cancer. Colorectal cancer was defined according to the International Classification of Diseases, Ninth Revision (ICD-9).
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>98% of deaths were identified through the registry of National Death Index 21 or by family report. Cause of death has been identified from death certificates or review of medical records. Paraffin-embedded tissue blocks have been obtained from hospitals where patients underwent respective surgeries. 22 Based on the availability of tumor tissue data on CASR expression, we included a total of 809 colorectal cancer cases diagnosed up to 2008 for this study.
Immunohistochemistry (IHC) of CASR and other markers
We constructed tissue microarrays [22] [23] [24] from colorectal cancer blocks, and performed IHC assays to measure tumor CASR expression. Tissue sections were deparaffinized, rehydrated and heated in a microwave for 15 min in Antigen Retrieval Citra Solution, pH 6 (BioGenex Laboratories, San Ramon, CA). Sections were incubated with Dual Endogenous Enzyme Block (Dako, Glostrup, Denmark), followed by the treatment with Protein Block Serum-Free (Dako). Slides were then incubated for 1 hr at room temperature with a rabbit polyclonal anti-CASR antibody (ab137408; Abcam, Cambridge, MA; dilution, 1:100). The primary antibody was visualized using EnVision1 System-HRP (Dako) with diaminobenzidine, and counterstained with hematoxylin. Sections processed with the replacement of primary antibody by Tris-buffered saline were used as a negative control. Immunohistochemical assessment for CASR was interpreted by a pathologist (Y. Masugi) blinded to other data. According to previously reported criteria, 8 tumor CASR expression was scored as 0 (no/minimal staining), 1 (weak staining), 2 (moderately intense staining) and 3 (intense staining) based on the staining intensity in colorectal carcinoma cells (Fig. 1) . CASR expression was observed predominantly in the cytoplasm and membrane of colorectal carcinoma cells, but occasionally in the nucleus of tumor cells. Consistent with the previous report, 8 we evaluated the intensity of cytoplasmic/membrane stain for scoring. We observed CASR expression in many types of cells, including colorectal normal epithelial cells, immune cells, endothelial cells, smooth muscle cells and ganglion cells. A second observer (Z.R.Q), unaware of other data, examined the CASR expression in 118 tumors. The concordance between the two observers was reasonable with a weighted kappa value of 0.71 (95% CI: 0.61-0.82). As shown in our previous studies, we have already conducted IHC assays on PTGS2 (cyclooxygenase-2) using anti-PTGS2 antibody 24 (clone CX229; mouse monoclonal antibody; dilution 1:300; Cayman Chemical), nuclear VDR (vitamin D receptor) using anti-VDR antibody 25 (dilution 1:500; rabbit polyclonal antibody; Novus Biologicals, NBP1-19478, Littleton) and CTNNB1 (b-catenin) using anti-CTNNB1 antibody 26 (clone 14; mouse monoclonal antibody; dilution 1:400; BD Transduction Laboratories).
Analysis of microsatellite instability, KRAS, BRAF, PIK3CA mutations and other markers
We extracted DNA from paraffin-embedded tissue and performed PCR and pyrosequencing for BRAF (codon 600), KRAS (codons 12, 13, 61 and 146) and PIK3CA (exons 9 and 20). 25, [27] [28] [29] [30] Microsatellite instability (MSI) status was identified using a 10-marker panel (BAT25, BAT26, BAT40, D2S123, D5S346, D17S250, D18S55, D18S56, D18S67 and D18S487). 28 Presence of instability in 30% of the markers was defined as MSI-high. 28 We also performed analyses of LINE-1 methylation 31 and eight CIMP-specific loci (CAC-NA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1). 32 Based on the previously established criteria, 33 methylation of six or more of the eight markers using the eight-marker CIMP panel was defined as CIMP-high.
Statistical analysis
Cox proportional hazard models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (95% CIs) of death as a result of colorectal cancer (for colorectal cancer-specific mortality) or death as a result of any cause (for overall mortality) according to tumor CASR expression (3-tiered; no or weak, moderate, intense). We conducted the analyses in each study as well as in the combined cohorts. For the main analyses, death as a result of colorectal cancer was the primary endpoint and death due to other causes was censored. In secondary analyses, death as a result of any cause was the end point. Patients were followed up until death or 1 June 2012 for the NHS and 31 January 2012 for the HPFS, whichever occurred first. We stratified by age at diagnosis, cohort (for the pooled analysis) and disease stage, as well as further adjusted for year of diagnosis, family history of colorectal cancer, tumor differentiation, tumor location, MSI status, CIMP status, LINE-1 methylation level, PTGS2 expression and KRAS, BRAF and PIK3CA mutations and nuclear expression of VDR and CTNNB1 (see Table 2 for the categorizations of these variables). There were 65 missing (7.9%) in tumor differentiation, 23 missing (2.9%) in MSI status, 65 missing (7.9%) in CIMP status, 20 missing (2.5%) in BRAF mutation, 22 (2.9%) missing in KRAS mutation, 67 missing (7.9%) in PIK3CA mutation, 21 missing (2.5%) in PTGS2 expression, 243 missing (30.1%) in nuclear VDR expression and 34 missing (4.2%) in nuclear CTNNB1 expression. For variables with missing, we assigned a separate ("missing") indicator variable and included those cases in the multivariate Cox models. 22 We confirmed that excluding cases with a missing variable did not materially alter results (data not shown).
As sensitivity analyses, we evaluated the association of tumor CASR expression with colorectal cancer-specific mortality according to disease stage (stage 1-2 vs. stage 3-4), and tumor differentiation (well to moderate versus poor), as well as categorized tumor CASR expression levels into binary variables (no or weak versus moderate-to-intense expression). We assessed the interaction by including the cross-product term of two variables of interest in the Cox model and performed a Wald test.
The X 2 test and analysis of variance were used to examine associations between different categorical variables and continuous variables, respectively. Two-sided hypothesis testing was used for all the comparisons. Analyses were done using SAS 9.3 (SAS institute, Cary, NC).
Results
Among 809 eligible patients with available tumor CASR data in these cohorts, 156 patients (19%) had no or weak expression, 461 (57%) had moderate expression and 192 (24%) had intense expression (Table 1 ). On average colorectal cancer patients were followed 10.8 years (interquartile range: 7.2, 15.1 years), during which there were 240 colorectal cancerspecific death and 427 all-cause mortality. As shown in Table  1 , moderate to intense tumor expression of CASR was associated with well to moderately differentiated tumors (p 5 0.04). Additionally, no or weak CASR expression was significantly associated with CIMP-high (p 5 0.02), PTGS2 negative (p < 0.001) and CTNNB1 negative (p 5 0.02) tumors. The included colorectal cancer cases with tumor CASR expression data were comparable to those colorectal cancer patients without the tumor CASR data (Supporting Information Table S1 ).
For the colorectal-cancer specific mortality analyses, the multivariable HRs comparing patients with intense tumor CASR expression versus patients with no or weak expression Table 2 ). The ageadjusted results were similar to multivariable results in women but strengthened in men. Adjusting for MSI status was primarily responsible for the observed strengthened association in men because patients with intense tumor CASR expression tended to have a lower prevalence of MSI-high, which is generally associated with a better prognosis. For men and women, the observed association appeared to be similar across strata of disease stage and tumor differentiation (all p values for interaction > 0.15).
For the all-cause mortality analyses, for the same comparison, the multivariate HRs (95% CIs) were 0.77 (0.48-1.25, ptrend 5 0.32) for the NHS, 0.78 (0.48-1.28, p-trend 5 0.29) for HPFS, and 0.81 (0.58-1.12, p-trend 5 0.22) for the combined cohorts (p values for interaction by gender 5 0.98, Table 3 ). As sensitivity analyses, we categorized tumor CASR expression into binary categories and found borderline significant association with colorectal cancer-specific mortality (HR: 0.71, 95% CI: 0.49-1.01) but not with all-cause mortality (HR: 0.84, 95% CI: 0.64-1.10, Supporting Information Table S3 ). Additionally, we have also conducted interaction analyses between tumor CASR expression with other known prognostic markers for CRC, including MSI, CIMP, KRAS and BRAF mutations. We did not observe any significant interactions (all p values for interactions > 0.20).
Discussion
In this large cohort of patients with colorectal cancer, we found that higher tumor CASR expression was associated with a modestly lower risk of colorectal cancer-specific mortality in both men and women. This association was independent of various clinical and molecular variables such as disease stage, tumor differentiation and tumor molecular features. In contrast, tumor CASR expression was not associated with all-cause mortality, indicating a potential role of CASR in colorectal cancer progression and pathogenesis.
In line with our findings, in vitro studies of colorectal cancer cell lines showed that higher CASR expression was positively associated with differentiation and apoptotic markers but inversely associated with proliferation markers. 3, 34, 35 Specifically, CASR/parathyroid hormone double knock-out mice showed significant up-regulation of markers of proliferation (e.g. increase in MKI67 (Ki-67) labeling index) and downregulation of markers of differentiation (e.g., decrease in CTNNB1 Ser-552 phosphorylation). However, restoration of CASR function considerably suppressed the tumorigenesis phenotype of colorectal cancer cells, suggesting CASR's increased apoptotic and differentiation potential. 3 Hence, CASR appeared to act as a tumor suppressor and a master regulator for maintaining normal intestinal cell turn over and homeostasis. 15, 36 We observed loss of CASR expression is significantly prevalent in the poorly differentiated tumors. This observation suggests a potential role of CASR in colorectal cancer pathogenesis and was supported by previous experimental studies. For example, intestinal epithelial cells loss of CASR expression demonstrated aggressive and highly malignant features such as lack of differentiation and adhesion of epithelial cells and absence of localization of E-cadherin at the cell surface. 37, 38 In addition, colonic epithelia isolated from intestine specific and global CASR knockout mice demonstrated 40 which induces growth suppression and enhances chemosensitivity of human colorectal cancer cells. 41 Furthermore, CASR activation stimulated paracrine secretion of WNT5A from myofibroblasts and expression of ROR2 in epithelial cells. 42 CASR-mediated WNT5A/ROR2 interaction increased epithelial differentiation and reduced expression of the receptor for tumor necrosis factor 1. 15, 39, 43 Collectively, our finding along with the experimental studies suggest that the modulators of CASR such as CASR agonists, including allosteric agonists, may be useful in therapeutic management of colorectal cancer, 5, 44, 45 which requires further investigation. We also observed higher prevalence of CIMP-high in tumors with no or weak CASR expression. In addition to genomic instability, epigenetic instability leads to irregular methylation of tumor suppressor genes. Hypermethylation of particular regions within the CpG islands encompassing the CASR gene promoter 2 was shown in 25% of neuroblastoma primary tumors and was associated with decreased CASR messenger RNA expression and several predictors of poor outcome in neuroblastomas, including MYC amplification. 46 One study reported that hypermethylation of CASR was detected in 69% of colorectal cancer tissues and 90% of lymph node metastatic tissues, as well as significantly correlated with decreased CASR expression. 35 These results suggest that epigenetic inactivation of CASR gene might play a role in colorectal carcinogenesis. In another study of CRC patients, 47 no statistically significant survival difference was observed by genotypes of CASR (A986S; rs1801725, G > T), although there was an indication that the TT genotype may be associated with a lower risk of CRC-specific mortality. It is possible that this genotype and other genotypes may reach statistical significance in genome-wide association studies with larger sample size and in other ethnicities. An alternative explanation is that the CASR regulation in CRC is independent of this single nucleotide polymorphism (SNP) and mainly affected by epigenetic changes and post-transcriptional modifications rather than genome level changes. Nonetheless, given the limited number of studies, more studies are warranted to evaluate the effect of SNPs in CASR gene on tumor CASR expression.
Our study has several strengths, including a large number of colorectal cancer cases from two prospective cohorts as well as extensive information on patient characteristics and various molecular features. Consequently, we were able to demonstrate an association of tumor CASR expression level with colorectal cancer-specific mortality, independent of clinical and other tumor characteristics.
In these cohorts, data on cancer treatment was limited. However, lack of such information was less likely to influence our results because such tumor CASR data were not available to the treating clinicians. We also expect minimal difference in access to the treatment in this cohort since minimal variation in socioeconomic status has been reported in both cohorts and both patient populations consisted of health care professionals. 48, 49 Our result should be validated in a cohort of mixed gender that is independent of the NHS and HPFS cohorts. In addition, data on cancer recurrence and metastasis were not available in either cohort. Because 5-year survival for metastatic colorectal cancer is 5-8%, the vast majority of patients with recurrence will die from metastatic disease. Based on the comprehensive mortality data, our study has captured the vast majority of recurrences because they will die from recurrent disease at some point and we have long follow-up on these patients.
In conclusion, this large prospective study of patients with colorectal cancer suggests that increased tumor CASR expression is an independent predictor of colorectal cancer-specific mortality. These findings need further confirmation and if confirmed, may lead to better understanding of colorectal cancer pathogenesis as well as exploring potential mechanisms of preventing or modulating colorectal cancer progression by targeting CASR.
